Table 1 Baseline characteristics
Characteristic, n (%) | ITT population | ctDNA-evaluable population, pooled treatment groups (n = 139) | ||
|---|---|---|---|---|
Atezolizumab + CT (n = 165) | Placebo + CT (n = 168) | |||
Age, years | <65 | 148 (90) | 139 (83) | 124 (89) |
≥65 | 17 (10) | 29 (17) | 15 (11) | |
ECOG PS | 0 | 157 (95) | 154 (92) | 135 (97) |
1 | 8 (5) | 14 (8) | 4 (3) | |
Self-reported race | White | 102 (62) | 108 (64) | 80 (58) |
Asian | 47 (28) | 41 (24) | 51 (37) | |
Black/African American | 9 (5) | 15 (9) | 4 (3) | |
Unknown/multiple | 7 (4) | 4 (2) | 4 (3) | |
AJCC stage | II | 118 (72) | 120 (71) | 99 (71) |
III | 47 (28) | 48 (29) | 40 (29) | |
PD-L1 status | Positive | 77 (47) | 75 (45) | 67 (48) |
Negative | 88 (53) | 93 (55) | 72 (52) | |
Primary tumor | T2 | 116 (70) | 123 (73) | 105 (76) |
T3 | 32 (19) | 34 (20) | 23 (17) | |
T4 | 17 (10) | 11 (7) | 11 (8) | |
Tumor grade | 1 | 2 (1) | 4 (2) | 2 (1) |
2 | 43 (26) | 43 (26) | 34 (24) | |
3 | 119 (72) | 119 (71) | 102 (73) | |
Missing | 1 (1) | 2 (1) | 1 (1) | |
Regional LN involvement | Yes | 56 (34) | 72 (43) | 54 (39) |
No | 109 (66) | 96 (57) | 85 (61) | |
Intratumoral TILs | <1% | 43 (26) | 39 (23) | 32 (23) |
≥1% | 122 (74) | 129 (77) | 107 (77) | |
Stromal TILs | <10% | 75 (45) | 86 (51) | 70 (50) |
≥10% | 90 (55) | 82 (49) | 69 (50) | |
